Myeloperoxidase in Chronic Kidney Disease |
| |
| Authors: | A Madhusudhana Rao Usha Anand C V Anand |
| |
| Institution: | (1) Department of Biochemistry, PSG Institute of Medical Sciences and Research, Coimbatore, 641004, Tamil Nadu, India; |
| |
| Abstract: | Numerous lines of evidence implicate a role of myeloperoxidase (MPO) in the pathogenesis of cardiovascular disease (CVD).
It is a well accepted fact that patients with chronic kidney disease (CKD) are at an increased risk for CVD. MPO is a pro-oxidant
enzyme which could be involved in the increased susceptibility of these patients to CVD. Hence, the levels of plasma MPO was
determined in healthy controls as well as in patients with CKD stratified with the level of their kidney failure as CKD stages
II–V (end stage renal disease)]. Plasma MPO was assayed by a spectrophotometric method. Serum urea and creatinine were estimated
on a clinical chemistry analyzer using standard laboratory procedures. The mean plasma MPO levels were significantly lower
with advancing stages of renal failure (P < 0.001). There was a positive correlation between MPO and GFR (r = +0.89, P < 0.001) and a negative correlation with urea (r = −0.85, P < 0.001) and creatinine (r = −0.82, P < 0.001). While an inverse association was observed between plasma MPO and urea in CKD patients, such an association was
not observed in control subjects (P = 0.43). In conclusion, the decline in plasma MPO levels may be due to the inhibitory effect of uraemic toxins on the enzyme. |
| |
| Keywords: | Chronic kidney disease MPO-hydrogen peroxide–chloride system Oxidative stress Uraemic toxins Cardiovascular disease |
| 本文献已被 PubMed SpringerLink 等数据库收录！ |
|
